AC Immune SA (ACIU)

AC Immune Income Statement

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	27.31	14.8	3.94	-	15.43
Revenue Growth (YoY)	84.51%	276.14%	-	-	-86.03%
Cost of Revenue	62.57	54.61	60.34	62.28	59.49
Gross Profit	-35.26	-39.81	-56.4	-62.28	-44.06
Selling, General & Admin	17.26	15.31	15.79	17.91	18.56
Other Operating Expenses	-0.14	-1.49	-1.34	-1.18	-1.35
Operating Expenses	17.12	13.82	14.45	16.73	17.2
Operating Income	-52.38	-53.62	-70.85	-79.01	-61.26
Interest Expense	-0.13	-0.18	-0.36	-0.58	-0.18
Interest & Investment Income	3.2	1.04	0.07	6.49	0.08
Currency Exchange Gain (Loss)	-1.6	-1.47	0.39	0.11	-0.56
EBT Excluding Unusual Items	-50.91	-54.22	-70.74	-72.99	-61.92
Pretax Income	-50.91	-54.22	-70.74	-72.99	-61.92
Income Tax Expense	0	0.01	0.01	0	-
Net Income	-50.92	-54.23	-70.75	-73	-61.92
Net Income to Common	-50.92	-54.23	-70.75	-73	-61.92
Shares Outstanding (Basic)	100	85	84	75	72
Shares Outstanding (Diluted)	100	85	84	75	72
Shares Change (YoY)	17.71%	1.36%	11.48%	4.24%	1.12%
EPS (Basic)	-0.51	-0.64	-0.85	-0.97	-0.86
EPS (Diluted)	-0.51	-0.64	-0.85	-0.97	-0.86
Free Cash Flow	65.27	-61.21	-74.81	-68.32	-61.22
Free Cash Flow Per Share	0.66	-0.72	-0.90	-0.91	-0.85
Gross Margin	-129.12%	-268.94%	-	-	-285.50%
Operating Margin	-191.80%	-362.30%	-1800.43%	-	-396.99%
Profit Margin	-186.44%	-366.41%	-1798.04%	-	-401.28%
Free Cash Flow Margin	238.99%	-413.55%	-1901.07%	-	-396.75%
EBITDA	-50.89	-51.95	-69.05	-77.11	-59.73
EBITDA Margin	-186.36%	-	-	-	-
D&A For EBITDA	1.49	1.67	1.79	1.9	1.54
EBIT	-52.38	-53.62	-70.85	-79.01	-61.26
EBIT Margin	-191.80%	-	-	-	-
Revenue as Reported	27.31	14.8	3.94	-	15.43

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q